|1.||Lee, Shiow-Ju: 7 articles (02/2015 - 03/2006)|
|2.||Yang, Cheng-Wei: 7 articles (02/2015 - 03/2006)|
|3.||Lee, Yue-Zhi: 6 articles (02/2015 - 08/2009)|
|4.||Cheng, Yung-Chi: 6 articles (01/2012 - 01/2004)|
|5.||Yin, Zhinan: 5 articles (09/2014 - 03/2006)|
|6.||Wang, Qingmin: 5 articles (09/2014 - 12/2010)|
|7.||Chao, Yu-Sheng: 5 articles (06/2013 - 08/2009)|
|8.||Gao, Wenli: 5 articles (01/2010 - 01/2004)|
|9.||Hsu, Hsing-Yu: 4 articles (02/2015 - 11/2011)|
|10.||Wang, Puyue: 4 articles (09/2014 - 09/2012)|
01/01/2013 - "A novel tylophorine analog W-8 up-regulates forkhead boxP3 expression and ameliorates murine colitis."
12/01/2012 - "A novel tylophorine analog NK-007 ameliorates colitis through inhibition of innate immune response."
12/01/2012 - "In this study, we synthesized (±)-tylophorine malate (NK-007), an analog of tylophorine (DCB3503), and analyzed its anti-inflammatory effect in vivo using a dextran sulfate sodium (DSS)-induced colitis model and an acetic acid-induced colitis model. "
02/10/2015 - "Tylophorine derivatives exhibit anti-cancer activities but their cellular targets remain unknown. "
01/01/2013 - "Tylophorine exerts anti-angiogenesis effects via VEGFR2 signaling pathway thus, may be a viable drug candidate in anti-angiogenesis and anti-cancer therapies."
01/01/2013 - "Tylophorine significantly inhibited neovascularization in sponge implant angiogenesis assay and also inhibited tumor angiogenesis and tumor growth in vivo. "
01/01/2012 - "Tylophorine analogs exhibit a broad range of pharmacological activities, including anti-cancer, anti-inflammatory, anti-autoimmune, and anti-virus effects. "
01/15/2004 - "Evaluation of (+)-S-tylophorine [DCB-3500 (NSC-717335)] and its analog DCB-3503 (NSC-716802) in the National Cancer Institute tumor screen showed a fairly uniform and potent inhibition of cell growth in all 60 cell lines (GI(50) approximately 10(-8) M). "
12/13/2012 - "The most potent compound from these assays, dibenzoquinoline 33b, showed improved solubility compared to tylophorine 9a, in vivo efficacies in a lung A549 xenografted tumor mouse model and a murine paw edema model, good bioavailability, and no significant neurotoxicity (as tested by a rota-rod test for motor coordination). "
11/01/2011 - "In addition, tylophovatine C (5) and 13a(S)-(+)-tylophorine (7) were found to exhibit potent in vivo anti-inflammation activities in a rat paw edema model. "
11/01/2010 - "Thus, our results suggest that tylophorine compounds are novel and potent anti-coronavirus agents that may be developed into therapeutic agents for treating TGEV or SARS CoV infection."
12/08/2010 - "These new findings demonstrate that these phenanthrene-based tylophorine derivatives (PBTs) represent another new template for antiviral studies and could be considered for novel therapy against plant virus infection. "
|5.||Severe Acute Respiratory Syndrome
11/01/2010 - "In addition, tylophorine compounds strongly reduced cytopathic effect in Vero 76 cells induced by human severe acute respiratory syndrome coronavirus (SARS CoV), with EC₅₀ values ranging from less than 5 to 340 nM. Moreover, a pharmacokinetic study demonstrated high and comparable oral bioavailabilities of 7-methoxycryptopleurine (52.7%) and the naturally occurring tylophorine (65.7%) in rats. "
|2.||Acetic Acid (Vinegar)
|5.||malic acid (malate)
|9.||Transcription Factor AP-1 (Transcription Factor AP 1)
|10.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|1.||Heterologous Transplantation (Xenotransplantation)